BioCentury | Oct 12, 2015
Company News

Visterra, U.S. Department of Health and Human Services infectious news

HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded Visterra a five-year contract worth up to $204.5 million to develop VIS410 to treat influenza A. The contract will fund preclinical toxicity studies, clinical trials, manufacturing...
BioCentury | Nov 10, 2014
Finance

Convert resurgence

Biotechs have raised $5.6 billion through convertible debt financings so far this year, the highest amount since 2006. Two bankers attributed the resurgence to a growing mid-cap space that is taking advantage of low interest...
BioCentury | Sep 15, 2014
Company News

Cytori, U.S. Department of Health and Human Services gene/cell therapy, other news

HHS's Biomedical Advanced Research and Development Authority (BARDA) exercised the first option in the company's September 2012 contract to develop a cell therapy to treat thermal burns from radiation injury. The product comprises a patient's...
BioCentury | Aug 4, 2014
Finance

Voucher leapfrog

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are hoping to use a newly acquired Priority Review voucher to jump ahead of Amgen Inc. (NASDAQ:AMGN) in the race to be first to market with a...
BioCentury | Mar 31, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) gained $0.60 to $7.20 last week after resubmitting an NDA to FDA for Iluvien fluocinolone acetonide intravitreal implant to treat diabetic macular edema (DME). The company said the resubmission...
BioCentury | Mar 3, 2014
Financial News

Ruthigen amends IPO

Ruthigen Inc. , Santa Rosa, Calif. Business: Infectious Date announced: 2/24/14 Type: IPO To be raised: Up to $20.4 million Shares: 2.2 million Price: $7.25-$9.25 (unit) Underwriter: Dawson James Securities Overallotment: 330,000 Note: Ruthigen, a subsidiary...
BioCentury | Nov 4, 2013
Finance

Calithera metabolizes

Calithera Biosciences Inc. has reinvented itself as a cancer metabolism play since it last raised money. A strong belief in the company's management lured back at least one existing investor in last week's $35 million...
BioCentury | May 20, 2013
Company News

Spectrum Pharmaceuticals cancer news

Spectrum disclosed in an SEC filing that it received a subpoena in April from the SEC to produce documents related to the company's 2012 earnings announcement that it expected a "change in ordering patterns" of...
BioCentury | Apr 29, 2013
Finance

Plenty supply; shrinking demand

Despite a gloomy quarterly report from PricewaterhouseCoopers and the National Venture Capital Association that noted a dearth in first-time financings for drug and device newcos in the U.S., at least one investor sees reason for...
BioCentury | Mar 25, 2013
Financial News

Harvard Apparatus amends IPO

Harvard Apparatus Regenerative Technology Inc. , Holliston, Mass. Business: Supply/Service Date announced: 3/20/13 Type: IPO To be raised: Up to $20.4 million Shares: 1.7 million Price: $10-$12 Underwriters: Summer Street; Maxim Group Overallotment: 255,000 Note: The...
Items per page:
1 - 10 of 48